Bioversys AG
BioVersys AG, a clinical stage biopharmaceutical company, focuses on identification, development, and commercialization of novel antibacterial products for serious life-threatening infections caused by multi-drug-resistant bacteria. It develops BV100 that is in Phase 3 clinical trial for carbapenem resistant Acinetobacter baumannii lung and blood stream infections; and in Phase 1 trial in patient… Read more
Market Cap & Net Worth: Bioversys AG (BIOV)
Bioversys AG (SW:BIOV) has a market capitalization of $181.07 Million (CHF165.80 Million) as of March 18, 2026. Listed on the SW stock exchange, this Switzerland-based company holds position #17019 globally and #87 in its home market, demonstrating a 10.94% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bioversys AG's stock price CHF28.40 by its total outstanding shares 5837986 (5.84 Million).
Bioversys AG Market Cap History: 2025 to 2026
Bioversys AG's market capitalization history from 2025 to 2026. Data shows growth from $155.57 Million to $181.07 Million (0.00% CAGR).
Bioversys AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bioversys AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of BIOV by Market Capitalization
Companies near Bioversys AG in the global market cap rankings as of March 18, 2026.
Key companies related to Bioversys AG by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #158 globally with a market cap of $118.01 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.58 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #158 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $118.01 Billion | $466.10 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.58 Billion | $756.91 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Bioversys AG Historical Marketcap From 2025 to 2026
Between 2025 and today, Bioversys AG's market cap moved from $155.57 Million to $ 181.07 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CHF181.07 Million | +16.39% |
| 2025 | CHF155.57 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Bioversys AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $181.07 Million USD |
| MoneyControl | $181.07 Million USD |
| MarketWatch | $181.07 Million USD |
| marketcap.company | $181.07 Million USD |
| Reuters | $181.07 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.